Skip to main content
. 2018 Feb 12;32(1):73–80. doi: 10.1007/s10557-018-6776-z

Fig. 1.

Fig. 1

Study design. After the statin administration period and informed consent is obtained, eligible patients are randomly allocated to the anagliptin group who receive twice a day anagliptin at 200 mg per day and to the sitagliptin group who receive once a day sitagliptin at 50 mg per day for 52 weeks, the study drug treatment period